Alimera Sciences Inc (ALIM)

$5.57

-0.02

(-0.36%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $5.57
    $5.60
    $5.57
    downward going graph

    0.0%

    Downside

    Day's Volatility :0.54%

    Upside

    0.54%

    downward going graph
  • $2.61
    $5.62
    $5.57
    downward going graph

    53.14%

    Downside

    52 Weeks Volatility :53.56%

    Upside

    0.89%

    downward going graph

Returns

PeriodAlimera Sciences IncIndex (Russel 2000)
3 Months
60.17%
0.0%
6 Months
42.6%
0.0%
1 Year
68.37%
0.0%
3 Years
121.83%
-20.2%

Highlights

Market Capitalization
293.1M
Book Value
$0.78
Earnings Per Share (EPS)
-0.25
PEG Ratio
0.0
Wall Street Target Price
5.67
Profit Margin
-23.74%
Operating Margin TTM
-10.0%
Return On Assets TTM
-0.58%
Return On Equity TTM
-197.04%
Revenue TTM
90.2M
Revenue Per Share TTM
2.41
Quarterly Revenue Growth YOY
69.89999999999999%
Gross Profit TTM
52.0M
EBITDA
10.2M
Diluted Eps TTM
-0.25
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.13
EPS Estimate Next Year
0.19
EPS Estimate Current Quarter
-0.06
EPS Estimate Next Quarter
-0.01

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Alimera Sciences Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1.8%

Current $5.57
Target $5.67

Company Financials

FY18Y/Y Change
Revenue
47.0M
↑ 30.79%
Net Income
-16.4M
↓ 25.54%
Net Profit Margin
-34.88%
↑ 26.38%
FY19Y/Y Change
Revenue
53.9M
↑ 14.85%
Net Income
-10.4M
↓ 36.26%
Net Profit Margin
-19.36%
↑ 15.52%
FY20Y/Y Change
Revenue
50.8M
↓ 5.79%
Net Income
-5.3M
↓ 48.87%
Net Profit Margin
-10.51%
↑ 8.85%
FY21Y/Y Change
Revenue
59.0M
↑ 16.15%
Net Income
-4.4M
↓ 18.11%
Net Profit Margin
-7.41%
↑ 3.1%
FY22Y/Y Change
Revenue
54.1M
↓ 8.3%
Net Income
-18.1M
↑ 314.16%
Net Profit Margin
-33.45%
↓ 26.04%
FY23Y/Y Change
Revenue
80.8M
↑ 49.19%
Net Income
-20.1M
↑ 11.18%
Net Profit Margin
-24.93%
↑ 8.52%
Q4 FY22Q/Q Change
Revenue
14.0M
↑ 3.17%
Net Income
-3.8M
↓ 28.1%
Net Profit Margin
-26.94%
↑ 11.72%
Q1 FY23Q/Q Change
Revenue
13.5M
↓ 3.44%
Net Income
-8.3M
↑ 119.6%
Net Profit Margin
-61.28%
↓ 34.34%
Q2 FY23Q/Q Change
Revenue
17.5M
↑ 29.47%
Net Income
-10.0M
↑ 20.82%
Net Profit Margin
-57.18%
↑ 4.1%
Q3 FY23Q/Q Change
Revenue
23.4M
↑ 33.22%
Net Income
-1.4M
↓ 86.5%
Net Profit Margin
-5.8%
↑ 51.38%
Q4 FY23Q/Q Change
Revenue
26.3M
↑ 12.59%
Net Income
-3.8M
↑ 179.25%
Net Profit Margin
-14.37%
↓ 8.57%
Q1 FY24Q/Q Change
Revenue
23.0M
↓ 12.53%
Net Income
-6.3M
↑ 65.33%
Net Profit Margin
-27.17%
↓ 12.8%
FY18Y/Y Change
Total Assets
54.1M
↓ 9.71%
Total Liabilities
51.4M
↑ 14.18%
FY19Y/Y Change
Total Assets
50.3M
↓ 7.02%
Total Liabilities
54.8M
↑ 6.55%
FY20Y/Y Change
Total Assets
50.9M
↑ 1.09%
Total Liabilities
58.8M
↑ 7.45%
FY21Y/Y Change
Total Assets
58.5M
↑ 15.07%
Total Liabilities
61.1M
↑ 3.9%
FY22Y/Y Change
Total Assets
42.6M
↓ 27.2%
Total Liabilities
63.5M
↑ 3.8%
FY23Y/Y Change
Total Assets
153.5M
↑ 260.37%
Total Liabilities
107.4M
↑ 69.19%
Q4 FY22Q/Q Change
Total Assets
42.6M
↓ 1.9%
Total Liabilities
63.5M
↑ 3.16%
Q1 FY23Q/Q Change
Total Assets
48.2M
↑ 13.23%
Total Liabilities
67.2M
↑ 5.84%
Q2 FY23Q/Q Change
Total Assets
154.9M
↑ 221.16%
Total Liabilities
108.7M
↑ 61.85%
Q3 FY23Q/Q Change
Total Assets
154.2M
↓ 0.47%
Total Liabilities
105.4M
↓ 3.07%
Q4 FY23Q/Q Change
Total Assets
153.5M
↓ 0.43%
Total Liabilities
107.4M
↑ 1.9%
Q1 FY24Q/Q Change
Total Assets
152.5M
↓ 0.68%
Total Liabilities
111.8M
↑ 4.17%
FY18Y/Y Change
Operating Cash Flow
-11.6M
↓ 10.26%
Investing Cash Flow
-175.0K
↓ 26.47%
Financing Cash Flow
950.0K
↓ 83.4%
FY19Y/Y Change
Operating Cash Flow
-4.2M
↓ 64.06%
Investing Cash Flow
-174.0K
↓ 0.57%
Financing Cash Flow
869.0K
↓ 8.53%
FY20Y/Y Change
Operating Cash Flow
-2.2M
↓ 47.18%
Investing Cash Flow
-620.0K
↑ 256.32%
Financing Cash Flow
3.9M
↑ 346.72%
FY21Y/Y Change
Operating Cash Flow
-3.2M
↑ 47.01%
Investing Cash Flow
-621.0K
↑ 0.16%
Financing Cash Flow
9.8M
↑ 153.04%
Q4 FY22Q/Q Change
Operating Cash Flow
-251.0K
↓ 86.88%
Investing Cash Flow
-75.4M
↑ 57926.15%
Financing Cash Flow
-193.0K
↓ 450.91%
Q1 FY23Q/Q Change
Operating Cash Flow
-2.2M
↑ 780.08%
Investing Cash Flow
-75.4M
↑ 0.0%
Financing Cash Flow
10.0M
↓ 5280.31%
Q2 FY23Q/Q Change
Operating Cash Flow
-6.0M
↑ 171.44%
Investing Cash Flow
-75.4M
↑ 0.0%
Financing Cash Flow
87.1M
↑ 771.42%

Technicals Summary

Sell

Neutral

Buy

Alimera Sciences Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Alimera Sciences Inc
Alimera Sciences Inc
1.27%
42.6%
68.37%
121.83%
121.83%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
7.56%
2.78%
45.55%
52.55%
67.01%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
7.53%
11.87%
3.28%
23.35%
23.35%
Zoetis Inc.
Zoetis Inc.
5.77%
-5.62%
-5.85%
-9.99%
57.03%
Viatris Inc.
Viatris Inc.
12.75%
-1.42%
12.21%
-15.03%
-28.03%
Catalent, Inc.
Catalent, Inc.
4.08%
11.91%
19.53%
-48.27%
2.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Alimera Sciences Inc
Alimera Sciences Inc
NA
NA
0.0
-0.13
-1.97
-0.01
NA
0.78
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
39.75
39.75
0.44
3.99
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.9
29.9
1.69
0.39
0.07
0.04
0.02
1.8
Zoetis Inc.
Zoetis Inc.
34.62
34.62
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
0.06
2.73
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.2
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Alimera Sciences Inc
Alimera Sciences Inc
Buy
$293.1M
121.83%
NA
-23.74%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.7B
67.01%
39.75
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$41.0B
23.35%
29.9
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$82.0B
57.03%
34.62
27.38%
Viatris Inc.
Viatris Inc.
Hold
$14.2B
-28.03%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.6B
2.08%
211.02
-28.44%

Insights on Alimera Sciences Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 26.30M → 23.01M (in $), with an average decrease of 12.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -1.35M → -6.25M (in $), with an average decrease of 122.3% per quarter

Institutional Holdings

  • Caligan Partners LP

    32.14%

  • Velan Capital Investment Management LP

    25.98%

  • Stonepine Capital Management Llc

    7.73%

  • BOOTHBAY FUND MANAGEMENT, LLC

    6.11%

  • Altium Capital Management, LP

    4.87%

  • Clearline Capital LP

    3.98%

Company Information

alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.

Organization
Alimera Sciences Inc
Employees
154
CEO
Mr. Richard S. Eiswirth Jr.
Industry
Health Technology

Discover More

FAQs